These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34028533)

  • 1. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy.
    Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Paasche A; Jávorszky N; Rinné S; Sutanto H; Büscher A; Foerster KI; Blank A; El-Battrawy I; Li X; Lang S; Tochtermann U; Kremer J; Arif R; Karck M; Decher N; van Loon G; Akin I; Borggrefe M; Kallenberger S; Heijman J; Haefeli WE; Katus HA; Schmidt C
    Cardiovasc Res; 2022 Jun; 118(7):1728-1741. PubMed ID: 34028533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D
    Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Foerster KI; El-Battrawy I; Lang S; Borggrefe M; Haefeli WE; Frey N; Schmidt C
    Front Physiol; 2020; 11():629421. PubMed ID: 33551849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
    Skarsfeldt MA; Jepps TA; Bomholtz SH; Abildgaard L; Sørensen US; Gregers E; Svendsen JH; Diness JG; Grunnet M; Schmitt N; Olesen SP; Bentzen BH
    Pflugers Arch; 2016 Apr; 468(4):643-54. PubMed ID: 26729267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
    Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the Role of K
    Mondéjar-Parreño G
    Front Biosci (Schol Ed); 2022 Nov; 14(4):31. PubMed ID: 36575841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
    Wiedmann F; Kiper AK; Bedoya M; Ratte A; Rinné S; Kraft M; Waibel M; Anad P; Wenzel W; González W; Katus HA; Decher N; Schmidt C
    Cell Physiol Biochem; 2019; 52(5):1223-1235. PubMed ID: 31001961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
    Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
    J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
    McEwen DP; Martens JR
    Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.
    Syeda F; Holmes AP; Yu TY; Tull S; Kuhlmann SM; Pavlovic D; Betney D; Riley G; Kucera JP; Jousset F; de Groot JR; Rohr S; Brown NA; Fabritz L; Kirchhof P
    J Am Coll Cardiol; 2016 Oct; 68(17):1881-1894. PubMed ID: 27765191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TASK-1 (KCNK3) and TASK-3 (KCNK9) tandem pore potassium channel antagonists stimulate breathing in isoflurane-anesthetized rats.
    Cotten JF
    Anesth Analg; 2013 Apr; 116(4):810-6. PubMed ID: 23460565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.